title: Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.
abstract: Oritavancin exhibited in vitro activity against 169 strains of vancomycin-susceptible, methicillin-resistant Staphylococcus aureus (MRSA) with MICs ranging from 0.03 to 1 μg/ml and against vancomycin-intermediate MRSA (VISA; n = 29), heterogeneous vancomycin-intermediate MRSA (hVISA; n = 5), and vancomycin-resistant MRSA (n = 5) strains, with MICs ranging from 0.12 to 4 μg/ml. For 10 MRSA isolates comprising 5 VISA and 5 hVISA strains, synergy between oritavancin and gentamicin, linezolid, or rifampin was observed against most of the strains tested using a time-kill method.
authors.affiliation: Hershey Medical Center, Hershey, Pennsylvania, USA.
authors.forename: Gengrong
authors.initials: G
authors.lastname: Lin
authors.affiliation: Hershey Medical Center, Hershey, Pennsylvania, USA.
authors.forename: Glenn
authors.initials: G
authors.lastname: Pankuch
authors.affiliation: Hershey Medical Center, Hershey, Pennsylvania, USA.
authors.forename: Peter C
authors.initials: PC
authors.lastname: Appelbaum
authors.affiliation: Hershey Medical Center, Hershey, Pennsylvania, USA KlaudiaShick@eurofinsUS.com.
authors.forename: Klaudia
authors.initials: K
authors.lastname: Kosowska-Shick
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004357:Drug Synergism; D006020:Glycopeptides / Q000494:pharmacology*; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; C100708:oritavancin; D014640:Vancomycin